Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries Dec 19, 2019
Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker Dec 16, 2019
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial Dec 13, 2019
Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker Oct 17, 2019
Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder Oct 7, 2019
Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019 Sep 25, 2019
Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial Sep 11, 2019
